

Enzene announces opening of new continuous biomanufacturing facility in US

05 September 2025 | News

Representing Enzene's first major manufacturing investment in the US



Governor Phil Murphy officially inaugurated the state-of-the-art biomanufacturing facility of Pune-based Enzene, a leading global continuously innovative development and manufacturing organization (CIDMO), marking a significant milestone in the expansion of global biotech capabilities in the United States.

Located in Hopewell, the new 80,000-sq.-ft. facility represents Enzene's first major manufacturing investment in the US, reinforcing its commitment to supporting pharmaceutical innovation and supply chain resilience across North America.

As well as fed-batch drug substance manufacturing, the site makes extensive use of the company's modular EnzeneX™ 2.0 platform, which is the world's first fully-connected continuous manufacturing™ (FCCM™) technology. The innovative platform is sustainable and scalable, and leverages optimised cell media and process analytical technology (PAT) to achieve 10-times the yield of conventional biomanufacturing and reduce the cost of goods sold (COGS) to as low as \$40 per gram.

“When Enzene — one of India’s most promising biotechnological companies — decided to launch its very first US manufacturing base, they knew there was nowhere better to do it than right here in New Jersey. Their decision reflects not only our state’s strength as a hub for global business and innovation, but also the deep cultural ties that bind New Jersey and India,” said Governor Phil Murphy. “This state-of-the-art facility represents the future of advanced manufacturing — ultimately creating hundreds of jobs and generating \$50 million in investment. As Enzene expands its presence here in New Jersey, we remain committed to supporting the company as it builds the world-class manufacturing ecosystem of tomorrow.”

“We are proud to bring our global expertise to the US and contribute to the advancement of biopharmaceutical manufacturing,” added Himanshu Gadgil, Ph.D., CEO of Enzene. “Our first-to-market manufacturing technology is forging a new path in biologics manufacturing that will provide a cost-efficient, high yield, US-based biomanufacturing solution for biopharmaceutical innovators, and complement our facilities in India to provide global supply solutions.”